Marc D. Kozin

Marc D. Kozin has served as a member of the Board of Managers of HCRx Holdings since October 2022.  Previously, Mr. Kozin served as Chairman of HCRx’s Senior Advisors Board and has been a Senior Advisor since 2013. He is also a senior advisor and former president of L.E.K. Consulting, a global management consulting firm. Mr. Kozin has three decades of global experience in strategy consulting and mergers and acquisition management. He also has substantial industry expertise advising biopharmaceutical, life sciences and medtech companies. During his tenure at L.E.K., Mr. Kozin advised senior executives in life sciences to help them identify new growth opportunities, build value, pursue highly-profitable mergers and acquisitions, and support sustained growth. He helped open that firm’s Boston office in 1987 and oversaw the growth of the firm’s U.S. operations including the company’s acquisition of shareholder value consulting firm Alcar in 1993. In 2002, Consulting Magazine named Mr. Kozin one of the 25 most influential consultants in recognition of his leadership and results for clients. He holds a B.A., magna cum laude, from Duke University, and an M.B.A. with distinction from The Wharton School at the University of Pennsylvania. Mr. Kozin currently serves as an outside board director of Dicerna Pharmaceuticals, Endocyte, UFP Technologies, OvaScience, Flex Pharma and VBL Therapeutics, all publicly held companies, and Frequency Tx, a privately held company.